Last reviewed · How we verify

Markman Biologics Microsurfaced ADM

McGuire Institute · FDA-approved active Biologic

Markman Biologics Microsurfaced ADM is an acellular dermal matrix (ADM) product with a modified surface designed to improve integration and reduce complications in reconstructive surgery.

Markman Biologics Microsurfaced ADM is an acellular dermal matrix (ADM) product with a modified surface designed to improve integration and reduce complications in reconstructive and aesthetic surgical applications. Used for Soft tissue reconstruction and augmentation in plastic and reconstructive surgery, Breast reconstruction, Abdominal wall reconstruction.

At a glance

Generic nameMarkman Biologics Microsurfaced ADM
SponsorMcGuire Institute
Drug classAcellular dermal matrix (ADM) / Tissue scaffold
ModalityBiologic
Therapeutic areaReconstructive and Aesthetic Surgery
PhaseFDA-approved

Mechanism of action

This is a biologic scaffold derived from human cadaveric skin with the cellular components removed, leaving behind the extracellular matrix. The microsurfacing technology modifies the surface properties to enhance tissue integration, reduce inflammatory response, and improve vascularization when used in reconstructive and plastic surgical applications.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: